Compare Neurocrine Biosciences Inc (NBIX) vs Onto Innovation (ONTO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Onto Innovation — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while Onto Innovation trades at $280.05 (market cap $13.80B). The key difference: Neurocrine Biosciences Inc and Onto Innovation are close in size by market cap, and Onto Innovation is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| NBIX | ONTO | |
|---|---|---|
Market Cap | $15.77B | $13.80B |
Sector | Health | Technology |
52-Week High | $185.50 | $378.45 |
52-Week Low | $123.10 | $106.04 |
Enterprise Value | $15.78B | $13.38B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
ONTO Innovation trades at $281.11, up 4.89% today, with strong analyst support (12 buy ratings, 0 hold/sell) and a $392.50 consensus price target suggesting 39.6% upside. The stock shows mixed earnings performance with a recent Q2 2026 beat ($1.93 vs. $1.69 expected) but misses in prior quarters. Revenue growth remains solid at $1.01B in 2025, though net income margin compressed to 11.84%. Technical indicators are neutral with support at $277 and resistance at $284.
Outlook remains positive given robust AI-driven semiconductor demand and a $1.1B+ backlog, but high valuation multiples (P/E 105.28, P/S 12.44) leave little room for execution missteps. Key risks include fiduciary investigation news, insider selling, and reliance on semiconductor cycle strength. Institutional confidence is high with BlackRock's $2.08B recent investment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Onto Innovation
Onto Innovation provides process control solutions for semiconductor manufacturing. Its inspection and metrology systems help chipmakers measure, analyze, and detect defects on wafers and advanced packages.
Read more on ONTO →
